🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. CP101

    Finch Therapeutics Group

    Clostridium Difficile Infection

    phase 2 mab completed

    1 trial

  2. CP101

    Finch Therapeutics Group

    Autism Spectrum Disorder

    phase 2 small molecule terminated

    1 trial

  3. CT7001, PF-07850327 round

    Pfizer Australia Pty Ltd

    Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  4. CUE-101

    Cue Biopharma

    Oropharyngeal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  5. CUE-101

    Cue Biopharma

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  6. CUVITRU - Ig subcutaneous human 20%

    Takeda

    COPD Exacerbation Acute

    phase 2 mab active

    1 trial

  7. CYCLOPHOSPHAMIDE MONOHYDRATE, VINORELBINE, Tecentriq 840 mg concentrate for solution for infusion

    Istituto Gentili S.r.l.

    Inoperable locally advanced or metastatic TNBC patients, previously treated with anti-PD-L1/PD1- regimens

    phase 2 small molecule active

    1 trial

  8. CYCLOPHOSPHAMIDE, YTB323, FLUDARABINE PHOSPHATE, TOCILIZUMAB, RITUXIMAB, RITUXIMAB

    Novartis Pharmaceuticals

    Diffuse cutaneous systemic sclerosis (dcSSc)

    phase 2 small molecule active

    1 trial

  9. CYSTAGON 150 mg hard capsules

    The George Institute

    Infectious diseases of respiratory system (COVID-19)

    phase 2 small molecule active

    1 trial

  10. Cadonilimab

    The First People's Hospital of Lianyungang

    Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  11. Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, PACLITAXEL, TOPOTECAN, farletuzumab ecteribulin

    Bristol-Myers Squibb Australia Pty Ltd

    Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    phase 2 small molecule active

    1 trial

  12. Calcio levofolinato Teva Generics 175 mg polvere per soluzione per infusione, BEVACIZUMAB , ZALTRAP 25 mg/ml concentrate for solution for infusion, Oxaliplatin 5 mg/ml concentrate for solution for infusion, Stivarga 40 mg film-coated tablets, FLUOROURACIL , FLUOROURACIL , Irinotecan Accord 20 mg/ml concentrato per soluzione per infusione, CAPECITABINE

    Fondazione Telethon ETS

    Patients with metastatic colorectal cancer (mCRC) RAS-mutant

    phase 2 small molecule active

    1 trial

  13. Calcium Folinate 10 mg/ml Solution for injection or infusion, Irinotecanhydrochloridetrihydraat Hikma 20 mg/ml, concentraat voor oplossing voor infusie, Fluorouracil Accord 50 mg/ml, oplossing voor injectie of infusie, Avastin 25 mg/ml concentrate for solution for infusion., Oxaliplatin Eugia 5 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    Patients with colorectal peritoneal metastases with a PCI-score of 1-20

    phase 2 small molecule active

    1 trial

  14. Calciumfolinat HEXAL 10 mg/ml Injektionslösung, Irinotecan HCl AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BNT321, FLUOROURACIL, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    BioNTech SE

    Resected (R0 or R1) pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  15. Camrelizumab and SBRT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 other active

    1 trial

  16. Capecitabina KERN PHARMA 150 mg comprimidos recubiertos con película EFG, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Irinotecán Hospira 20 mg/mL concentrado para solución para perfusión EFG., Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Capecitabina

    The George Institute

    Localised Colon Cancer (stage II-III)

    phase 2 small molecule active

    1 trial

  17. Carboplatin

    Children's Hospital of Fudan University

    Central Nervous System Nongerminomatous Germ Cell Tumor

    phase 2 small molecule completed

    1 trial

  18. Carboplatin 10 mg/ml Concentrate for Solution for Infusion, DOMVANALIMAB, Paclitaxel 6 mg/ml concentrate for solution for infusion, Zimberelimab

    Gilead Sciences Pty Limited

    Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  19. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, JNJ-61186372, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Janssen-Cilag International N.V.

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  20. Carboplatino Hikma 10 mg/ml soluzione per infusione, Avastin 25 mg/ml concentrate for solution for infusion., Cisplatino Accord Healthcare Italia 1 mg/ml concentrato per soluzione per infusione, JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Tumours, Gynecological

    phase 2 small molecule active

    1 trial

  21. Celecoxib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Oral Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  22. Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.

    Lxo Ireland Designated Activity Company

    Liver Transplant Rejection

    phase 2 other completed

    1 trial

  23. Cell therapy for Inclusion Body Myositis (IBM) by muscle injection of autologous uncultured Adipose-Derived Stromal Vascular Fraction (ADSVF): a phase I trial

    Pari Pharma GmbH

    Inclusion Body Myositis

    phase 2 other active

    1 trial

  24. Cemiplimab

    Regeneron UK Limited

    Locally Recurrent Oral Cavity Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources